1. Home
  2. ASMB vs AUTL Comparison

ASMB vs AUTL Comparison

Compare ASMB & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Assembly Biosciences Inc.

ASMB

Assembly Biosciences Inc.

HOLD

Current Price

$25.50

Market Cap

442.9M

Sector

Health Care

ML Signal

HOLD

Logo Autolus Therapeutics plc

AUTL

Autolus Therapeutics plc

HOLD

Current Price

$1.59

Market Cap

388.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ASMB
AUTL
Founded
2005
2014
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
442.9M
388.6M
IPO Year
2010
2025

Fundamental Metrics

Financial Performance
Metric
ASMB
AUTL
Price
$25.50
$1.59
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
4
Target Price
$44.20
$8.50
AVG Volume (30 Days)
184.0K
1.3M
Earning Date
05-06-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
91.78
N/A
EPS
N/A
N/A
Revenue
N/A
$10,120,000.00
Revenue This Year
N/A
$80.32
Revenue Next Year
$638.39
$53.96
P/E Ratio
N/A
N/A
Revenue Growth
N/A
496.00
52 Week Low
$16.81
$1.18
52 Week High
$39.71
$2.70

Technical Indicators

Market Signals
Indicator
ASMB
AUTL
Relative Strength Index (RSI) 50.55 51.05
Support Level $22.49 $1.41
Resistance Level $30.80 $1.73
Average True Range (ATR) 1.52 0.12
MACD 0.44 0.00
Stochastic Oscillator 59.56 57.33

Price Performance

Historical Comparison
ASMB
AUTL

About ASMB Assembly Biosciences Inc.

Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.

About AUTL Autolus Therapeutics plc

Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.

Share on Social Networks: